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Recently, numerous protein-based nanomedicine platforms have been intensively 
explored. These systems are usually composed of self-assembling proteins that form controllable 
systems with different shapes and types. A particular type of the self-assembling proteins is the 
cage protein bacterioferritin (Bfr), a hollow protein that belongs to the ferritin superfamily of 
iron storage proteins. Bfr is composed of 24 identical protomers with 12 heme cofactors 
intercalated between adjacent subunits. Bfr has an 8 nm interior diameter and a 12 nm exterior 
diameter amenable for controllable modification. Previous investigations in the Honek laboratory 
involved engineering the Bfr cage proteins towards controlling the encapsulation of various guest 
molecules within its cavity. Polyhistidine amino acid sequences (His6-tags) were added to each 
of the C-termini of the Bfr protein subunits, which point towards the interior cavity of the 
protein, and successfully utilized as selective affinity interaction sites to bind several cargos such 
as a gold nanoparticle (AuNP), and a fluorescently labeled tetrameric protein, streptavidin. 
Additionally, the intrinsic heme cofactors were modified in different ways and reintroduced to 
the Bfr cage protein providing another approach for engineering this complex system. In the 
current study, the previously established engineering methodologies were utilized to investigate 
the possibility of engineering the Bfr cavity to be more hydrophobic and to examine its 
capability for encapsulating different hydrophobic molecules. The complexation between two 
different types of fatty acid-based molecules and the His6-Bfr cage protein was successfully 
achieved and analyzed. The two proof of concept guests studied in our laboratory were: a 
synthesized nonadecanoyl-nitrilotriacetic acid micelle and a commercially available lipid that has 
an NTA functionality preloaded with nickel ion. Also, another approach for labeling the heme 
propionate groups with long alkyl chains was investigated. Two long alkyl chain primary amines 
iv 
 
were successfully added to the heme; however, the poor aqueous solubility of these hydrophobic 
analogues acts like a barrier towards their successful incorporation into the Bfr cage. The results 
gained from the above investigations highlight novel applications of not only Bfr, but also other 
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1. Chapter 1: Introduction 
1.1. Overview 
Recently, applications of bionanoparticles (BNP) in the field of medicine have 
intensively expanded; several nanoparticulate materials have been engineered in various ways 
for drug delivery and imaging purposes. A particular type of bionanoparticle is the cage protein, 
which consists of multiple subunits that self-assemble naturally to form varying hollow protein 
structures. Varieties of engineered cage proteins have the ability to host novel guest molecules 
within their cavity. Of interest to the current study is the cage protein bacterioferritin (Bfr), a 
hollow protein that belongs to the ferritin superfamily of iron storage proteins. Bfr is composed 
of 24 identical subunits with 12 heme cofactors intercalated between adjacent subunits. Bfr has 
an 8 nm interior diameter and a 12 nm exterior diameter amenable for controllable modification. 
The purpose of the presented experimental research is to further expand the versatility of Bfr as a 
bionanoparticle toward hydrophobic guest encapsulation and potentially molecular delivery. 
Changes in the hydrophobic character of the Bfr interior cavity through heme cofactor 
modification and through a series of controlled host-guest interactions have been explored. In 
this chapter, some nanomedical applications of proteins will be outlined, and the relevant 
background information on cage proteins, bacterioferritin, and encapsulation strategies will be 
discussed.   
1.2. Proteins: platforms for nanomedical applications 
Recent developments in the fields of bionanotechnology and medicinal chemistry have 
been focused upon the rational design of BNPs to be used as nanomedicine platforms.  BNPs are 
preferred over completely synthetic NP for several reasons; such as, their well-organized 




sequence profile through which surface and intrinsic characteristics can be controlled by 
mutagenesis.
1
 In particular, proteins and protein-like structures; for example, viral capsids, virus-
like particles and protein cages like ferritins, heat shock proteins, vault cages and enzyme 
complexes (Figure 1.1),  have been extensively studied as building blocks for BNP synthesis due 
to their biocompatibility, biodegradability and low toxicity.
2  
A variety of these supramolecular 
units having a high degree of spatial organization and well-characterized self-assembly motifs 
has emerged as promising theranostic agents. Genetic alteration of protein scaffolds, such as the 
insertion of heterologous peptides or chemoselective bioconjugates into the protein shell has 
been used to produce scaffolds with medically relevant functionalization.
3-8
 
Recently, selective chemical modification of protein scaffolds has achieved remarkable 
development. For example, the large surface area of protein-based NPs has been exploited for the 
attachment of multiple copies of affinity ligands, a process which has been shown to increase 
biomolecular target affinity.
9 
An example of such enhancement was reported by Khor and 
collaborators who have modified the cowpea mosaic virus (CPMV) with multivalent display of 
peptide sequences on the surface which have increased its binding affinity to various targets.
10
 
Moreover, the surface modification of specific amino acid residues in viral capsids along with 
the alteration in their interior and interface have created viral capsids encapsulating molecular 
cargos such as the antitumor agent doxorubicin (DOX), polymeric sulphonic acid, and externally 
displayed antibody 19G2.
11-13
 Other cage proteins such as small heat shock protein (Figure 1.1), 
whose interior and exterior have been genetically or chemically modified, have been used as a 
delivery platform for fluorescein, RGD 4C peptide, anti-CD4 antibody, and doxorubicin.
14-16
 In 
fact, the unique container-like architecture of cage proteins has attracted extensive interest that 



















 are some of the proteins that have been successfully utilized as drug delivery 
platforms (DDP).  
 
Figure 1.1: Structural illustration of some protein cages used as BNP for medical applications. The internal diameter of 
each protein is indicated. Images were generated in Chimera software using PDB IDs: 1BFR, 3VQK, 4ZOR, 2QZV, 
5D7Y, 1CWP. 
 
1.3. Bionanoparticles and hydrophobic drug delivery 
Due to the fact that the vast majority of therapeutic agents are small hydrophobic 
molecules, efficient delivery of these hydrophobic dyes or drugs into their target cells has been 
the focus of attention for years. While chemical modification of new or existent hydrophobic 
compounds has been the “classical” approach to improve their pharmacokinetics and 
pharmacodynamic properties, many new investigations have focused on developing new 




carriers can provide new environments to incorporate various therapeutics, thus overcoming 
limitations caused by poor solubility of conventional drugs and improve their delivery.
36
 Typical 




and polymer conjugations such as 
poly(ethylene glycol) (PEG).
39
 Despite the success of dendrimers and PEG-conjugated BNPs, 
which have been approved for clinical use, the size limitation and the lack of cellular targeting 
are critical drawbacks that made further development necessary. A newly developed BNP 
targeted for hydrophobic delivery can be found in the report of the sophisticated engineering of 
the Vault NP, which is a large ribonucleoprotein, encapsulating a recombinant nanodisc that is 
capable of carrying hydrophobic compounds (Figure 1.2).
40
 Another attempt to generate a ferritin 
cage protein with a hydrophobic interior was proposed by a group of researchers from the 
University of Pennsylvania  who has successfully designed a ferritin-like protein, DNA-binding 
proteins from starved cells (Dps), with a hydrophobic cavity through mutation of about 120 
amino acids on the inside surface of the protein shell,
41
 although previous  studies suggested that 
hydrophobic mutation of  hollow proteins may affect their stability.
42,43
 The modified Dps cage 
protein exhibited reasonable stability and retained its natural capability of iron mineralization 





Figure 1.2: Schematic illustration of the nanodisk- all-trans retinoic acid (NDI-ATRA) formation and encapsulation into 
the vault nanoparticle. Dimyristoylphosphatidylcholine (DMPC) and dimyristoylphosphatidylglycerol (DMPG) lipids 
interact with Apolipoprotein-AI- binding domain INT ( ΔApo-AI-INT) to form a discoidal phospholipid bilayer nanodisk 
(NDI). The amphipathic helices of ΔApo-AI-INT run perpendicular to the phospholipid acyl chains in a double belt-like 
manner around the circumference of the nanodisk. Addition of ATRA during formation results in the drug’s absorption 
into the lipoprotein complex. NDI packaging into the vault nanoparticle is achieved by the vault binding-domain INT. 
The figure was taken with permission from Rome, L. et al.40 
1.4. Designing BNPs with enhanced target specificity 
Despite the tremendous advances in drug design and discovery especially in the field of 
chemotherapy, the lack of target specificity contributes for most of the unfavorable side effects 
of these therapeutics. Nonspecific binding of toxic drugs to uninfected, healthy tissues would 
result in unpleasant, if not serious, effects that have been a reason for withdrawal of a large 
number of drugs from clinical usage. Different strategies have been developed to overcome low 






1.4.1. Passive targeting 
Most of the clinically used NP-based drugs nowadays are passively targeted therapeutics, 
passively targeting a drug to certain types of cells, mainly tumor cells, involve the usage of drug 
formulations that will initially circumvent drug clearance through natural body defense 
mechanisms by the enhanced permeability and retention effect (EPR) of blood vessels and 
abnormal lymph drainage within diseased tissues (Figure 1.3) producing better therapeutic effect 
with substantially lower systemic toxicity.
44
 Passive targeting involves modification of various 
elements that will enhance drug retention and accumulation within the body such as, molecular 
weight, surface charge, size and hydrophobicity of the carrier; surface modification of drug 
carriers was achieved by coating the surface with hydrophilic polymers or surfactants. PEG, 
poloxomer and polysorbate have been widely used for surface coating of drug delivery systems; 
for example, designed paclitaxil loaded NP fixed with a polymeric coat of PEG-polylactic acid 
exhibited high kinetic stability and prolonged retention time in blood circulation.
45
 In a different 
study, DOX-loaded gelatin and PEGylated gelatin- based NPs presented increased accumulation 
rates within tumor cells compared to free drug.
46
 Despite substantial improvement in therapeutic 
effects of drug systems targeted through passive targeting strategies, such drug formulations 
undergo non-specific uptake by healthy tissues leading to unpleasant, sometimes fatal, adverse 
effects due to the accumulation of drug in those tissues. Therefore, more efficient targeting 
pathways are being developed such as active targeting and drug-carrier-based targeting 






Figure 1.3: Tumor vascular pathophysiology and EPR effect in NP delivery. The normal (A) and the tumor (B) tissue 
microvasculature are represented. NPs with size between 10-100 nm could permeate through the leaky vasculature of the 
tumor tissue, while the intact blood vessels of normal tissues do not allow NPs leakage; therefore, the systemic toxicity will 
be substantially decreased, this figure was modified with permission from Upreti, M. et al.44 
1.4.2. Active targeting 
 This targeting strategy involves the use of chemical and/or biological affinity ligands like 
peptides, monoclonal antibodies, and sugar chains, to direct NPs to their cellular targets; such 
ligands have featured recognition to their cellular targets which are usually overexpressed in 
diseased cells. An example of this strategy is Calicheamicin-conjugated anti-CD33 monoclonal 
antibodies that exhibited increased selectivity against acute myeloid leukemia cell lines that 
express CD33.
47 
Another approach is based on targeting unique receptors expressed on the 
surface of malignant cells through NPs delivery systems linked to targeting peptides; upon 
binding, the drug system undergoes receptor-mediated endocytosis. For instance, two separate 




 receptors in hepatoma cells 
through transferrin-conjugated drugs and hematoporphyrin-modified albumin NPs, respectively. 
Another promising form of active targeting via aptamers, which are RNA or DNA 




specificity combined with low immunogenicity of aptamers has attracted numerous researchers 
to design drug delivery formulations that contain aptamers as affinity ligands. Aptamer-based 
NPs have been employed as diagnostic as well as therapeutic agents; an example of their 
diagnostic applications is the design of fluorescent DNA-silver nanoclusters that were able to 
detect the presence of cancer cells early; detection signals were generated as a result of 
conformational changes that occurred upon binding of the aptamer to the cancer cells.
50
 
Moreover, several studies have confirmed the enhancement of targeted cytotoxicity of aptamer-
based therapeutics against different types of cancer. An example can be found in the study of a 
paclitaxel-loaded NP conjugated to DNA aptamer that exhibited high affinity to the MUC1 
protein that is overexpressed in adenocarcinoma cells. The investigated drug platform presented 
high accumulation rates and hence increased cytotoxicity against breast cancer cell line models.
51
 
Targeting tumor cells via aptamers was found to be a method of choice in terms of selectivity; 
however, the high cost of aptamer production and optimization can be a critical disadvantage. 
1.5. The Ferritin superfamily 
Of interest to this current study, ferritin cage proteins have been an important family 
among drug delivery platforms. Ferritins are globular iron storage proteins found in all life 
kingdoms, they are responsible for maintaining the iron concentration inside the cell within a 
normal range.
52,53
 The ferritin superfamily can be divided into three subfamilies which are the 
classical ferritins (Ftns), bacterioferritin (Bfr) and the DNA-binding proteins from starved cells 
(Dps).
53
 Proteins of this family consist of subunits that naturally self-assemble into roughly 
spherical cages with outstanding thermal and chemical stability.
52
  
Several ferritin/apoferritin DDPs have been developed based on their assembly and 




pH control has been utilized to encapsulate Daunomycin, an anthracycline antibiotic used in the 
treatment of certain types of cancer, and deliver it to cancer cells.
54
 Another investigation 
reported the loading of a gadolinium complex, a contrasting agent used in magnetic resonance 




Figure 1.4: Schematic representation of the dissociation of apoferritin into subunits at pH 2, followed by its reformation 
at pH 7. In this way the solution components are trapped within the protein interior. The figure was modified from 
reference 55, and regenerated using the software program Chimera using PDB ID: 2W0O. 
Moreover, a number of ferritin-based drug delivery platforms with an enhanced cellular 
specificity were designed; although ferritins are known for their natural cellular targeting through 
interaction with transferrin receptors, a number of affinity motifs, such as antibodies and primary 
peptides, were introduced to the ferritin nanocage surface in order to direct ferritin molecules to 
specific cells. Surface cysteine and lysine residues were exploited for the chemical addition of 
different dyes and targeting peptides to the exterior surface of the ferritin cage protein
56-60
 
(Figure 1.5). For instance, a ferritin-based DDP with enhanced cellular recognition was designed 




4C, which exhibits tumor cell specificity, was incorporated on the exterior of human ferritin. 
This was accomplished by genetically modifying the external surface of the 12 nm multisubunit 
protein ferritin without affecting the structural or functional properties of the protein.
60
 Some 
other applications of ferritin cages are listed in Table 1.
61 
 
Figure 1.5: Schematic representation of various strategies adopted for addition of novel affinity motifs to the ferritin 
surface. This figure was taken in part and modified from reference 62.  
Table 1: Applications and sources of ferritin used in bionanotechnology.61  
     Application                                        Core composition                                  Source                     
 
MRI contrast agent                                           Iron oxyhydroxide                      Transfected human H-chain63 
 
Phosphate removal from water                            Ferric phosphate                       Pyrococcus furiosus ferritin 64 
 
Quantum label                                                      ZnSe                                        Horse spleen apoferritin65 
 
Semi-conductor template                                     CdS/ZnSe                                 Apoferritin 66 
 
Au NPs                                                                  Au                                          Engineered human H-chain Ferritin67 
 






1.6. Bacterioferritin (Bfr) 
1.6.1. Sequence identity 
Recently, researchers in the Honek laboratory have been exploring the multiprotein 
complex Bfr from Escherichia coli (E. coli) as a cage protein and have investigated its possible 
application in the field of nanotechnology. Twenty-four identical subunits self-assemble to form 
the spherical hollow protein Bfr with inner and outer diameters of approximately 8 nm and 12 
nm, respectively. Primarily, Bfr acts as an organelle that stores excess iron through the 
deposition of the solid Fe
3+
, as an oxide, within its core.
69
 Despite the high degree of structural 
conservation among members of the ferritin superfamily, the sequence identity between Bfr and 
other ferritins is less than 20%.
70
 Since ferritin subfamilies share the same function which is 
deposition of oxidized iron within their cores, the residues involved in this process, also known 
as the ferroxidase centre, are highly conserved in all of the ferritin family members.
71
 
1.6.2. Ferroxidase centre 
Iron is essential for a wide variety of cellular processes. Ferritins play a crucial role in 
sustaining the cellular iron needs as well as maintaining iron homeostasis. Members of the 
ferritin superfamilies contain a dinuclear ferroxidase (iron) centre formed by intra-subunits for 
ferritins and Bfr, or inter-subunit interactions in Dps.
72,73
 In the Bfr cage protein, the ferroxidase 
centre is composed of two iron binding sites in each subunit, each consisting of 4 glutamate 
residues (Glu18, Glu51, Glu94, and Glu127). Both Glu51 and Glu127 bridge two Fe
2+
, while the 
other two Glu residues bridge two histidines (His54 and His130) (Figure 1.6).
74 
This centre is 
responsible for binding the Fe
2+
 entering through the protein shell pores and oxidizing it to Fe
3+
, 




accommodate a maximum of ~4500 iron atoms in its core;
75
 however, the presence of 
intercalated 12 heme-b molecules between Bfr subunits is unique. Although the function of these 
heme molecules is not well identified, it has been reported that heme molecules play a role in 
releasing the iron ions from the Bfr core and enhance the iron core formation as well.
76
 
1.6.3. Structural composition 
Ferritin and Bfr have highly conserved quaternary structures. Two aspects are involved in 
the structure discussion of ferritin and Bfr. The first aspect concerns the functional unit of the 
ferroxidase center, the dimer (ɑ2), and the second concerns the intact 24-mer (ɑ24) quaternary 
structure. Each Bfr subunit is composed of 158 amino acids, with a molecular weight (MW) of 
18.5 kiloDaltons (kDa). In total, the MW of the 24-mer protein complex is 443.9 kDa. The single 





N-terminus of each Bfr subunit faces the exterior surface while the C-terminus is 
situated to face the interior cavity of the cage protein. According to the three dimensional 
structure of Bfr, three types of channels are formed in the protein shell; eight are 3-fold 
symmetry channels, six are 4-fold symmetry channels and 24 are B-type channels (Figure 1.6). 
All of these channels mediate the transfer of iron in and out of the Bfr shell.
77
 The Bfr 24-mer 
complex has an interior diameter of approximately 8 nm and an outer diameter of about 12 nm, 







Figure 1.6: Structural overview of Bfr and the ferroxidase centre found at the interior surface of Bfr subunits. (A) The 
functional unit of Bfr, the dimer, is shown in blue within a 2-fold symmetry, one of the 3-fold symmetry channels is shown 
in purple (B), and a 4-fold symmetry channel shown in red in (c). Illustration of the heme, in yellow, situated between two 
adjacent protomers along with a focused image of the ferroxidase centre (E) showing the residues involved in 
coordinating 2 iron atoms (blue spheres). Images generated using Chimera software (PDB ID: 1BFR). 
1.6.4. Heme cofactors 
Heme is an iron Fe
2+
 containing cofactor, which is found in many metalloproteins, which 
are also known as hemoproteins, such as cytochromes, hemoglobin and myoglobin. Among the 
ferritin superfamily, Bfr is the only member that contains heme cofactors within its quaternary 
structure. Heme binding pockets exist between Bfr dimer interfaces, where two methionine 
residues contributed from two adjacent subunits coordinate one heme cofactor. According to the 
crystal structure of Bfr, heme propionate groups face the interior cavity of the protein. Although 
the function of these heme molecules is not well identified, it has been reported that the heme 
molecules play a role in releasing Fe
2+ 






 The presence of heme in hemeproteins has provided additional sites for protein 
modification where useful functionalities can be labeled to the heme, through the modification of 
its propionate groups, and thus to the hemeprotein.
78,79
 Different heme analogues have been 
synthesized and incorporated into the Bfr cage protein in our laboratory, in order to increase the 
versatility of this bionanoscaffold.
80 
Further discussions of heme modifications will be presented 
in Chapter 2.  
1.7. Encapsulation of functional guest molecules within cage proteins  
The encapsulation of various guest molecules within DDP involves different kinds of 
host-guest interactions. In fact, understanding the methods used to encapsulate guest molecules is 
of critical importance to develop successful molecular delivery platforms. To date, the demand 
for designing effective DDP with well-understood and controllable host-guest interactions has 
been an active area of research. The encapsulation of novel guest molecules within cage proteins 
usually requires the disassembly of these cages, which allows various guest molecules to interact 
with the interior surface of the host protein. Upon interaction, protein cages reform their cage 
structures trapping the desired guest molecules within their cavities. Three strategies for guest 
molecules encapsulation are discussed below. 
1.7.1. Concentration-dependent encapsulation  
This strategy is one of the least favorable methods for encapsulation. The methodology is 
based on the disassembly of cage proteins in the presence of high concentrations of a guest 
molecule. Upon reassembly, the cage protein will encapsulate unpredictable quantities of the 
guest molecules within the cavity.
81 
There are two critical disadvantages of this method; first is 




repulsive force could be a barrier toward successful encapsulation. The second reason is the 
limited control over the encapsulation process, since variation in the number of guest molecules 
encapsulated can be observed under identical experimental studies. This non-specific strategy 
can be useful when high concentrations of guest molecules are available and it could be of 
preference to some researchers since no protein modification is needed. For instance, 
encapsulation of a small drug, cisplatin, into ferritin was accomplished utilizing concentration-
based encapsulation experiments.
82
 Another example of this approach was the encapsulation of 
horseradish peroxidase within cowpea chlorotic mottle virus (CCMV) using high concentrations 
of the guest enzyme.
83
 
1.7.2. Covalent and genetically engineered encapsulation 
In this second strategy, covalent bonds that can be formed between the host protein and 
the guest molecules can be utilized to achieve stable irreversible encapsulation. Although such 
interaction can be favorable for applications that do not require the release of the guest molecules 
such as cell imaging and enzyme encapsulations, however, other applications such as molecular 
delivery requires the encapsulated guests to be released upon reaching their targets. In case of 
cage proteins and peptides, genetic modification of the inner surface can provide covalent 
linkage to the guest molecules; example of this approach was reported by Douglas and 
coworkers, who were able to engineer bacteriophage P22 virus toward the encapsulation of a 
wide variety of enzymes such as CelB glycosidase and alcohol dehydrogenase.
84,85 
Moreover, 
direct labeling of amino acids can be utilized to mediate covalent encapsulation of various 
functional molecules. The incorporation of a cysteine (Cys) residue by site-specific mutagenesis 




was utilized to covalently encapsulate a photodynamic therapeutic within the virus cage, and the 
loaded host protein was successfully directed to cancer cell surfaces.
86
 
1.7.3. Non-covalent directed encapsulation  
Non-covalent host-guest interaction creates a dynamic interaction, which may be 
beneficial for releasing different cargos in many studies. For example, a gold nanoparticle 
(AuNP) displaying a nitrilotriacetic acid (NTA) moiety on the surface was non-covalently bound 
to the Vault associated protein which was genetically modified to have a His-tag on its internal 
surface.
87
  The non-covalent interaction between His-tags and the NTA moieties have provided a 
strong bond for a controllable cargo encapsulation.  Similarly, the genetic addition of binding 
motifs to scaffolding proteins has increased the versatility of these nanodevices; for example, a 
chimeric viral capsid that has the ability to bind different types of therapeutic siRNA was 
designed through the fusion of a p19 RNA binding protein to the Hepatitis B virus.
88
  
In fact, a number of non-covalent directed encapsulation studies were investigated in our 
laboratory using the Bfr cage protein, which was genetically engineered by Dr. Uthaiwan 
Suttisansanee onto the C-termini to have hexahistidine tags,
89
 as a scaffold. His-tags have been 
shown to promote several host-guest interactions between the engineered Bfr and a variety of 
functional guest molecules containing NTA functionalities (Figure1.7). For example, the large 
tetrameric protein streptavidin and 5 nm AuNPs were successfully encapsulated in separate 
experiments in the 8 nm cavity of Bfr.
80
 These His-tags were found to be essential to the 
encapsulation process since the absence of interactions between the cargo and the encapsulating 




host-guest interaction, the NTA-histidine interaction, is highly specific as its dissociation 




Figure 1.7: Illustration of two basic structures required for metal-mediated affinity interactions involved in the Bfr 
engineering. (A) X-ray structure of bacterioferritin with modeled His-tag residues at the C-terminus of the Bfr subunits 
(B) nitrilotriacetic acid (NTA) functionality coordinating a nickel atom (red) with two histidine residues. This affinity 
interaction was utilized for encapsulation of two large guest molecules within Bfr by the Honek group. 
1.8. Motivations for pursuing Bfr engineering 
 The success in developing the Bfr cage protein to be an effective molecular delivery 
platform has opened a window for further explorations. The purpose of the work presented in 
this thesis is to develop the Bfr cage protein to serve as a delivery platform for hydrophobic 
guest molecules. Two approaches are designed to develop the Bfr cage to accommodate 
structures with long alkyl chains: firstly, the heme cofactors would be chemically modified with 
long alkyl chains attached to the heme propionate groups. Secondly, the His6-tags, which have 
been previously attached to the Bfr subunits, would be involved in a series of Ni
+ 
mediated 
affinity interactions with two long alkyl chains structures with NTA functionalities. Creating a 
controllable hydrophobic environment within the Bfr core would allow for several drugs or dyes 

























Chapter 2: Heme Cofactor Modification 
2.1. Introduction  
Unlike other members of the ferritin superfamily, Bfr is the only family member that 
contains heme cofactors. Heme is a protoporphyrin with an iron atom in the centre of the 
porphyrin ring. In the cage of Bfr, twelve heme cofactors can be incorporated into a single Bfr 
capsule; heme cofactors are coordinated through two methionine residues, M52, from separate 
subunits (Figure 2.1). The protein-binding pockets for heme are on the inner face of Bfr and the 
propionate groups of the heme point towards the interior cavity of the protein. The nature of the 
heme propionate groups provided opportunities for the addition of novel functionalities and 
ligands to the heme cofactor and thus Bfr. Moreover, the success in individually modifying the 
heme propionate groups has increased the complexity of heme labeling.
91,92
 These factors have 
made heme an ideal candidate to explore the further development of Bfr as a platform for 
bionanotechnology. For the past few years, several synthetic heme analogues were synthesized 
and incorporated into Bfr in the Honek laboratory; such as, labeling the heme with a fluorescent 
coumarin derivative, 7-diethylaminocoumarin-3-carbohydrazide (DCCH) and a fluorescein 
derivative, 5-(aminoacetamido) fluorescein (AAF) in two separate experiments (Figure 
2.2.A&B).
80
 A new approach was designed to utilize heme cofactors to change the hydrophilic 
character of the Bfr cavity into a hydrophobic cage in order to expand the versatility of Bfr as a 





Figure 2.1: Heme cofactors are coordinated between two Bfr subunits. (A) Twelve heme cofactors can be incorporated 
into Bfr, eight are shown in red. (B) Illustration of heme positioning between two Bfr subunits with heme propionate 
groups pointing to the interior of the protein (C). Images were generated using Chimera software (PDB ID: 1BFR) 
 
In this chapter heme modification of the propionate groups with a variety of lengths of 
alkyl chains, namely N-butylamine (NBA, CH3(CH2)3NH2), octadecylamine (OA, 
CH3(CH2)17NH2) and dodecylamine (DA, CH3(CH2)11NH2) will be explored. Different strategies 
for heme propionate group activation and labeling were investigated in order to obtain the ideal 
conditions for the synthesis of hydrophobic heme analogues; experimental procedures and results 
will be discussed. Also, attempts to introduce heme-DA analogues to the His6-Bfr will be 





Figure 2.2: Structures of some of the heme analogues synthesized in the Honek laboratory and successfully introduced 
into bacterioferritin (A): (a) heme-mono-DCCH, (b) heme-bis-DCCH, (c) heme-mono-AAF and (d) heme-bis-AAF. Also, 
in B a modeled fluorescent dye attached to each of the propionate groups of heme cofactors are shown in the Bfr structure 




Figure 2.3: Illustration of the investigated approach to incorporate hydrophobic heme analogues into the Bfr. C18 amine 
(cyan) are linked to each of the two propanoic acids of each of the twelve heme cofactors. Image was generated in 








2.2.1. Materials  
Hemin (Sigma-Aldrich, Buchs, Switzerland), Polystyrene-carbodiimide (Biotage, Hengoed, 
United Kingdom), N-hydroxysuccinimide (1-hydroxy-2,5-pyrrolidinedione) (Sigma-Aldrich, Louis, 
MO, USA), N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC) (Sigma-
Aldrich, Oakville, ON, Canada), N,N′-dicyclohexylcarbodiimide (DCC) (Sigma-Aldrich, 
Oakville, ON, Canada), and oxalyl chloride (Sigma-Aldrich, Oakville, ON, Canada) were used 
as received. Dimethylformamide and dimethyl sulfoxide (Sigma-Aldrich, Sheboygan Falls, WI, 
USA), pyridine and dichloromethane (Sigma-Aldrich, Oakville, ON, Canada) all in anhydrous 
form were utilized from a Sure-Seal
TM
 bottle and were stored over dry 4 Å molecular sieves 
before use for synthesis. N-Butylamine was purchased from Spruce Street, Saint Louis, MO, 
USA and octadecylamine and dodecylamine from Sigma-Aldrich, Milwaukee, WI, USA. 
Polystyrene benzaldehyde (PS-benzaldehyde) (1.2 mmol/g) and polystyrene sulfonyl chloride 
(PS-TsCl) (2.0 mmol/g) (Biotage, Hengoed, United Kingdom) were used as provided by the 
manufacturer. 
2.2.2. Safety statement 
All solvents and chemicals were handled with appropriate glove wear, laboratory coats, 
safety goggles, and in a fume hood. Chromatography using solvents was performed in a fume 
hood, and silica resins and thin layer chromatography (TLC) plates were disposed of properly 






2.2.3. Activation of heme propionate groups using carbodiimide and N-hydroxysuccinimide 
(NHS) 
In previous work, the reaction of heme with carbodiimide and NHS has been used to 
achieve the activation of heme propionate groups. Heme-NHS served as a semi-stable 
intermediate, which could be used directly to label heme with molecules containing primary 
amines or hydrazide functionalities (Scheme 2.1). 
The procedure for the heme-NHS synthesis reaction was previously reported in the 
literature.
92
 Hemin ((Chloro(protoporphyrin)iron(III); 200 mg,  307 µmol) was first stirred with 
polystyrene-anchored dicyclohexylcarbodiimide (PS-DCC) (954 mg, 2.8 equiv., 130 µmol/g) in 
anhydrous DMF (3.2 mL) at 23 °C for 10 minutes, followed by the addition of NHS (88 mg, 2.5 
equiv., 760 µmol). The solution was stirred for 1 h, at 100 
0
C in a Biotage® Initiator Microwave 
Synthesizer (Scheme 2.2.a). After one hour, the reaction was allowed to come to room 
temperature and the mixture was filtered using a column with glass wool packed at the bottom to 





Scheme 2.1: Reaction mechanism for the synthesis of heme-NHS using a polystyrene linked carbodiimide. 
The soluble hemin-containing compounds were precipitated by addition of a 10x volume 
of chilled, dry isopropanol. This was followed by centrifugation at 5000g for 20 minutes in a 
VWR clinical 100 centrifuge. The dark pellet was collected, dried under vacuum and stored 
away from light exposure at -20 °C. The product was analyzed using TLC on silica gel plates 
with dichloromethane and methanol (9:1) as elution solvent.  The final heme-NHS product, 





2.2.4. Heme-NHS reaction with NBA, DA and OA 
Following the same protocol used previously in the Honek laboratory, heme-NBA was 
synthesized by mixing heme-NHS (3.4 mg, 4.2 μmol) with NBA (1.2 mg, 16 μmol, 4 equiv.) and 
stirring in anhydrous DMF (500 μL) at 100 °C for 40 minutes in a Biotage
®
 Initiator Microwave 
Synthesizer. 
 
Scheme 2.2.a: Heme-NHS synthesis from heme activated with PS-carbodiimide and then reacted with NHS. 
A number of trial reactions to synthesize the heme-OA analogues were performed under 
various reaction conditions. Different equivalents of OA were added to heme-NHS (20 mg, 24.6 
μmol) and then dissolved in either CHCl3 or DMF; the reactions were heated in the Biotage 




C, and 120 
0
C for 1 h, 2 h and 5 h.  In another 
experiment OA (16.5 mg, 61.5 μmol, 2.5 equiv.) was first melted at 100 
0
C for 20 minutes, 
followed by adding heme-NHS (20 mg, 24.6 μmol). The mixture was kept at 100 
0
C for 1 h in a 
Precision
TM
 Gravity Convection oven. Once cooled to room temperature, the product was taken 
up in 500 µL hexane, washed with equal volumes of DMF (3X) and analyzed using mass 




using scavenger resins.  In one experiment polystyrene sulfonyl chloride (PS-TsCl) (24.6 mg, 
39.3 µmol, 2 equiv.) was added to the product of the heme-OA reaction, stirred for 5 h at 23 
0
C 
followed by heating at 50 
0
C for two hours in the Biotage® synthesizer. The beads were filtered 
from the solution using glass wool and the flow through solution was analyzed using MS. In 
another experiment, polystyrene benzaldehyde resin (63 mg, 57.8 µmol, 3 equiv.) was stirred 
with the product of heme-OA reaction, two drops of methanol were added to catalyze the 
reaction; the reaction was stirred for 18 h. A column packed at the bottom with glass wool was 
used to filter out the beads and the solution was analyzed using MS (Scheme 2.2.b). 
 Heme-DA was synthesized by mixing heme-NHS (20 mg, 24.6 μmol) with DA (13.3 
mg, 72 μmol, 3 equiv.) and stirring in anhydrous DMF (1mL) at 100 °C for 1 h in a Biotage® 
synthesizer. The reaction time was increased to 3 h in another experiment to assess the time 
effect on the chemical reaction (Scheme 2.2.b). 
 
Scheme 2.2.b: Reaction of heme-NHS with primary alkyl amines 
2.2.5. Reaction of heme with DA and OA in the presence of carbodiimides 
Heme-DA was synthesized by dissolving hemin chloride (50 mg, 76.6 µmol) in 1.5 mL 




(35.5 mg, 191.5 µmol, 2.5 equiv.). The solution was heated at 100 
0
C for 2 h in Biotage® 
synthesizer. Attempted syntheses of heme-OA using the previous procedure were conducted, 
using 1.5 and 2.5 equiv. of OA, and the temperature and reaction times were varied in different 
experiments as well. Dicyclohexylcarbodiimide (DCC) was used as an alternative coupling agent 
for another set of reactions using the same protocol as well. In addition, following a reported 
procedure for heme-bis-OA synthesis in the literature,
79
 an experiment was carried out where 
hemin chloride (20 mg, 30.6 µmol) was stirred in anhydrous pyridine (1.5 mL) for 30 min at 0 
0
C; DCC (15.7 mg, 76.5 µmol, 2.5 equiv.) was added and the solution was stirred for 1.5 h. Then 
OA (20.6 mg, 76.5 µmol, 2.5 equiv.) in pyridine (1 mL) was gently added to the previous 
mixture and stirred at 0 
0
C for 24 h. A similar reaction was repeated at room temperature and 
was monitored for 12 days. The products of both reactions were analyzed using MS (Scheme 
2.3). 
 
Scheme 2.3: Reaction of heme with DA and OA in the presence of carbodiimides 
2.2.6. Reaction of heme with DA and OA in the presence of oxalyl chloride 
Based on a protocol from the literature, a procedure that
 
involved the activation of 
protoporphyrin IX propionate groups using oxalyl chloride was attempted.
93




started by suspending hemin chloride (50 mg, 76.6 µmol) in anhydrous dichloromethane (10 
mL). Oxalyl chloride (100 µL, 153.2 µmol, 2 equiv.) was added along with anhydrous DMF (5 
µL). The solutions were stirred for 1 h, solvents were evaporated under vacuum and the greenish 
brown intermediate product, heme-dichloride, was collected (Scheme 2.4.a). The heme-
dichloride intermediate was dissolved in anhydrous pyridine (5 mL) mixed with anhydrous DMF 
(2 mL). DA (35.5 mg, 191.5 µmol, 2.5 equiv.) or OA (51.6 mg, 191.5 µmol, 2.5 equiv.) were 
dissolved in anhydrous pyridine (1.5 mL) and gently added to the solution and stirred for 10 h in 
two separate experiments (Scheme 2.4.b).  
 
Scheme 2.4.a: Reaction of hemin chloride with oxalyl chloride to form mono and bis chloro heme intermediate. 
 




2.2.7. Reaction of protoporphyrin IX with OD and DA in presence of oxalyl chloride 
Protoporphyrin IX-DA (PPIX-DA) analogue was synthesized by suspending PPIX (40 
mg, 53.3 µmole) in anhydrous dichloromethane (15 mL). Oxalyl chloride (75 µL, 106.6 µmole, 2 
equiv.) was added along with 2 drops of DMF; the mixture was stirred for 1 before the solvent 
was evaporated under vacuum and the greenish brown solid product was collected. This material 
was dissolved in anhydrous pyridine (3 mL) and DMF (2 mL). DA (24.6 mg, 133.2 µmole, 2.5 
equiv.) was dissolved in anhydrous pyridine (1 mL) and added slowly to the above reaction 
mixture, which was stirred for 10 h; reaction product was analyzed using MS. The same 
procedure was followed for the synthesis of PPIX-OD adduct, using 30 mg of OA (133.2 µmole, 
2.5 equiv.) 
2.2.8. Purification of heme-DA products  
Purifications of products of both heme-NHS and hemin chloride reactions with DA were 
performed. Heme-DA analogues were purified on a Biotage® KP-SIL SNAP column with a 
Biotage® Isolera chromatography system. Solvents were completely evaporated under vacuum, 
and the solid residues were dissolved in 2 mL dichloromethane (CH2Cl2); this was then added to 
a Biotage® KP-SIL samplet (1 g) where a tight brown band would form at the top of the samplet 
cartridge. Once dry, the samplet cartridge was added to the top of a KP-SIL cartridge (10 g resin) 
that had been equilibrated with 50 mL of a 9:1 chloroform:methanol mixture. The samplet 
cartridge was then added to the top of the column, and an elution gradient was applied (100% 
CH2Cl2 to 100% methanol in a total volume of 290 mL). Several solvent conditions to separate 





2.2.9. Attempts for incorporating heme-DA analogues to the His-Bfr cage protein 
Heme-DA in DMF or DMSO (7 x 10
-8
 mol, 1.0 equiv.) was added to His6-tag Bfr (7.0 x 
10
-8
 mol) buffered with 0.2 M MES and 1.0 M NaCl at pH 6.5. The mixture was then placed in a 
water bath at 80 °C for 10 minutes. After 10 minutes of incubation the mixture was allowed to 
cool to 23 °C. The precipitated heme was removed through centrifugation at 7650g for 10 
minutes. Protein samples were purified using a GE SephacrylTM S-300HR resin, with a void 
volume of 99.05 mL, a running flow rate of 0.5 mL/min, and collecting fraction volumes of 1 
mL.  
2.2.10. MS experimentation 
  
Crude reaction samples were prepared by diluting 5 μL of a 16 mM crude reaction into 
50 μL of 1:1 MeCN: H2O with 0.2% formic acid, and further diluting 5 μL of this dilution into 












2.3. Results and Discussion 
Different methodologies for the synthesis of various hydrophobic heme analogues were 
explored. The results of the attempted syntheses will be presented and discussed in this section. 
2.3.1. Heme preparation and modification 
2.3.1.1. Heme activation with NHS 
The first work with heme labeling in the Honek laboratory, was started by an 
undergraduate student, Denise Lieuson, who had successfully developed a method for heme-
NHS synthesis, followed by labeling of the activated heme with N-butylamine (NBA). This work 
had set the stage for more heme analogue syntheses conducted by Anton van der Ven.
80
 Hemin 
chloride, which is identical to heme with the exception that a chloride coordinates the heme iron, 
is highly soluble in DMF; therefore, most of the reactions were carried out in anhydrous DMF. 
The method that was eventually used for the majority of heme labeling reactions involved 
mixing hemin with a polystyrene bead linked carbodiimide (PS-DCC) and NHS in DMF. Heme 
activated by carbodiimide reacts with NHS to various extents; however, the majority of heme is 
fully activated to heme-bis-NHS, with some heme-mono-NHS detected (Figure 2.4). The heme-
mono-NHS product was not separated from the bis-NHS product because purification can be 
performed after further reaction of the mixture with various amines. All equivalents were 
calculated under the assumption that the product, heme-NHS, is a 100% heme-bis-NHS. Heme 
reaction with NHS appeared to proceed toward completion, as monitored by MS, and formed 
largely the heme-bis-NHS product, which is consistent with what was reported by previous 
students. The product was analyzed using thin layer chromatography (TLC) on silica gel plates 




ester)). MS analysis using a Thermo Scientific LTQ
TM
 gave m/z for M
+
= 713 (monoester, 
predicted: 713.55), 810 (bis-ester, predicted: 810.63). 
 
 
Figure 2.4: Mass spectrometry results of two heme-NHS reactions. Heme-bis-NHS has an expected mass of 810.63 g/mole, 
the heme-mono-NHS predicted mass is 713.55 g/mole, and free hemin chloride has an expected mass of 651.94 g/mole. 
Reaction (A) appeared to be more complete than B, since the predominant masses in the spectrum are for the bis and 
mono heme-NHS adducts, and the free hemin is hardly detectable in A.   
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2.3.1.2. Heme-NHS modification with functional alkyl labels 
Previous work has established that heme can be labeled with a small ligand, N-
butylamine. This reaction was used as a standard for the sake of consistency with previous work 
and to explore the effect of the size of the alkylamine on the heme labeling efficiency. Heme-
NBA was produced through the mixing of heme-NHS with NBA in anhydrous DMF for 40 
minutes at 100 
0
C. The heme analogue produced was mainly the heme-bis-NBA product. This 
was likely due to the small size of the alkylamine, having small steric hindrance on the bis-

















                                        
Figure 2.5: MS results of the heme-NHS reaction with N-butylamine (NBA). (A) The heme-mono-NBA substitute could be 
observed as a small peak with a calculated molar mass of 671.61 g/mol, while the most predominant compound was found 
to be the heme-bis-NBA analogue with a calculated molar mass of 726.73 g/mol. Structures of the mono- and bis-modified 







Attempted reactions to produce heme-bis-OA adduct were conducted, where different 
equivalents of OA were added to a solution of heme-NHS in DMF and stirred at 100-150 
0
C for 
different time periods (1 - 5 h). Surprisingly, no modified heme was detected in any of these 
reactions products, with evidence for the presence of the free label, OA (expected mass is 269.51 
g/mol), (Figure 2.6.a). The disappearance of the heme adduct peaks could be due to the fact that 
the free long alkyl chain amine is suppressing the ionization of other compounds in the 
electrospray field; therefore, attempts to decrease the amounts of the free OA from the product 
using different scavenger resins were performed. All resins were polystyrene-anchored so they 
could be filtered out from solution using glass wool after the scavenging experiments were 
completed. The protocols for the scavenger resins, PS-benzaldehyde and PS-TsCl, were adapted 
from the protocols reported in the Biotage
®
 products catalog for removing similar amines. 
According to the intensity of the peak corresponding to the free amine, PS-benzaldehyde resin 
seemed to bind the free OA more efficiently than the PS-TsCl resin (Figure 2.6.a) consequently 
it was chosen for all subsequent scavenger resin experiments. In addition, a peak corresponding 
to the potassium adduct of the heme-mono-OA was detected in the PS-benzaldehyde treated 
heme-OA (5 h reaction at 115 
0
C) (Figure 2.6.b), with no evidence for the formation of the 
heme-bis-OA. Taking into account that OA is only partially soluble in DMF which might be a 
barrier that prevents the completion of the reaction, two different experiments were conducted; in 
the first experiment DMF was replaced by chloroform to enhance the solubility of OA in the 
reaction solution; however, solvent replacement did not make any difference in the MS results 
and only heme-mono-OA was observed again. In the second experiment consisted in performing 
a solid-based reaction in which the heme-NHS was completely melted and sufficient equivalents 
of OA were then added. The mixture was heated at 100 
0




the produc was then dissolved in hexane and washed twice with DMF. Results of this reaction 
revealed the formation of relatively higher amounts of the mono adduct in the hexane layer 
where other heme compounds where detected in the DMF wash, which indicated that the 
solubilities of the heme-OA analogues are different from free heme and heme-NHS. Therefore, 
solvent extraction using hexane was performed for early detection of the hydrophobic heme-OA 
adduct formation based on color change in the hexane layer in addition to TLC and MS analysis. 
The reason behind the failure in the production of heme-bis-OA could be due to two reasons. 
Firstly, the length of the alkyl chain in the heme-mono-OA adduct, which is 18 carbons in 
length, might contribute a larger steric hindrance to the bis-adduct formation due to its greater 
dynamic conformational size. Secondly, the close proximity of the NHS group in the heme-
mono-OA adduct might not be as accessible as in the heme-bis-NHS. In order to examine these 
two hypotheses, further experimentation with shorter alkylamines and using different heme 










               
Figure 2.6.a: MS results for heme-NHS reaction with OA. (A) Predominant peaks correspond to free OA expected mass 
(269.51 g/mol) observed peak 270, and its DMF non-covalent complex (m/z+= 343). (B) Intensity of free OA signal 
decreased after PS-benzaldehyde treatment with a little enhancement of the heme product signals.  
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Figure 2.6.b: MS results of the product of one heme-NHS reaction with OA. (A) K+-heme-mono-OA adduct, expected 
mass is 906.07 g/mol, detected in the hexane layer of the solid based reaction. Structure of the K+ adduct is displayed in B. 
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A reaction of heme-NHS with a shorter amine was necessary to evaluate the efficiency of 
this heme labeling methodology and to investigate the possibility of producing shorter bis-alkyl 
heme analogues. Two reactions of heme-NHS with DA for 1 h and 3 h at 100 
0
C in the Biotage® 
Initiator microwave synthesizer were conducted. The MS analysis of both reactions indicated the 
formation of both mono and bis heme-DA products with characteristic m/z values of 783 and 
950 respectively (Figure 2.7), with no significant effect by time variation. In comparison to the 
OA reaction, heme-DA labeling appeared to be more efficient which indicates that the length of 












Figure 2.7: MS results of heme-NHS reaction with DA. Both heme-mono- and -bis- DA analogues were detected, expected 
masses are 783.8 g/mol and 951.1 g/mol respectively. Structures of heme-mono-DA and heme-bis-DA are displayed.  
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2.3.1.3. Reaction of heme chloride with OA and DA in presence of carbodiimides 
Attempts to produce heme-bis-OA through activation of the heme propionate groups 
using direct carbodiimide activation were investigated. Heme chloride was stirred with EDC and 
different equivalents of OA in anhydrous DMF or anhydrous pyridine, reaction times and 
temperatures were applied in different experiments. MS analysis of the results of these reactions 
showed evidence of formation of the heme-mono-OA adduct and EDC-activated heme (Figure 
2.8). Moreover, the intensity of the mass peaks that correspond to the mono-substituted analogue 
appeared to be larger with pyridine as solvent compared to the reactions where DMF was used as 
a solvent. This could be due to the enhanced solubility of EDC in pyridine compared to DMF. 
However, the variation in time and temperature did not have any effect on the reaction. TLC 
analyses of the various coupling reactions described in this thesis were also undertaken to 
confirm the MS analyses, and were consistent with the conclusions drawn from the relative mass 
peak intensities obtained through mass spectrometry. Although the synthesis of heme-bis-OA 




 the same 
procedure was followed with no evidence of the heme-bis-OA formation. Moreover, to 
investigate the influence of temperature on this reaction, hemin chloride was stirred with DCC in 
pyridine for 1.5 h followed by addition of OA; the reaction was then stirred at 23 
0
C and 
monitored for 12 days. Aliquots from the reaction were taken on a daily basis and analyzed by 
MS. The formation of heme-mono-OA with an expected mass of 867.9 g/mol was observed since 
day 2, but no evidence of the heme-bis-OA until day 7 was obtained, wherein a small peak 
corresponding to the expected mass of the bis-adduct, 1119.4 g/mol, was detected. The intensity 
of this signal increased significantly from day 7 to 10; simultaneously, disappearance of the 




heme-mono-OA was converted into the heme-bis-OA analogue. In addition, mass peaks 
corresponding to free heme, free OA, and mono and fully (bis) heme-DCC activated compounds 
were observed throughout the reaction, which indicated that the heme does not completely react 
with DCC and OA. After ten days, significant changes in the reaction solution’s odor, color and 
MS results were observed (Figure 2.8).  
Moreover, a reaction of heme with DA in the presence of EDC was conducted to further 
examine the influence of alkyl chain length. In this case, heating the hemin chloride with excess 
EDC and DA was sufficient to form heme-mono-DA and heme-bis-DA analogues, which is 
consistent with the hypothesis of the influence of the alkyl chain length on the degree of 















   
Figure 2.8: MS results of hemin chloride after numerous days with OA in presence of DCC. (a) Reported results for the 
day 7 of the reaction showed small signals for the heme-mono-OA m/z+(867) and signals for heme-bis-OA m/z+ (1119) 
whose intensity increased significantly by day 10 (b). Signals corresponding to heme-bis-DCC (1028) and heme-mono-OA 
+DCC (1046) were detected throughout the analysis.  
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2.3.1.4. Reaction of hemin chloride with OA and DA in the presence of oxalyl chloride 
For further confirmation of the effect on the success of the coupling reaction by the type 
of leaving group and activation reagent, further experimentation with a smaller activation group, 
the chloride atom, was conducted (Figure 2.10). The reaction of the heme with oxalyl chloride to 
form the heme-bis-DA analogue was reported in the literature.
93 
The procedure was followed and 
the MS results indicated the formation of both mono- and bis-DA heme substitution, which is 
consistent with the published findings;
93
 however, the yield of heme-bis-DA appeared to be 
relatively lower than those of the heme-NHS and heme-EDC. This could be due to the instability 
of the heme-bis-chloride intermediate since the chloride atom should be more readily replaced by 
nucleophiles. Similar reactions with OA were conducted, heme-mono-OA was clearly detected 
in MS results; however, heme-bis-OA related peaks had very low intensity (Figure 2.9). 
Analyses of these results suggested that the small size of the leaving group could lead to a faster 
and more complete reaction. However due to the instability of the heme-Cl intermediate, the 
overall yield of this reaction was very low. Further experimentation of the heme-Cl reaction with 
OA, and utilizing different conditions in solvent, temperature, and time, could be investigated in 






Figure 2.9: Mass spectrometry results of heme-Cl reactions with OA and DA. (A) a clear indication of the formation of 
heme-mono-OA adduct at m/z 867.58 which matches its calculated MW. (B) MS results of DA labeling reaction showed 
the successful synthesis of heme-bis-DA at m/z 950.69, and heme-mono-DA at m/z 783.45, predicted MWs for both 
analogues are 951.1 g/mol and 783.8 g/mol respectively. 
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Furthermore, the effect of the presence of iron in the porphyrin ring on such labeling 
reactions was assessed through conducting an experiment in which hemin chloride was replaced 
by protoporphyrin IX (Figure 2.10), which is an iron-free heme analogue. The results of the iron 
free analogue reaction in the presence of oxalyl chloride were similar to those of the heme 
reaction under the same conditions, where only the mono-OA adduct was observed in the PPIX-
OA experiment and both of PPIX-mono and bis-DA were detected by MS. This suggested that 
the presence of Fe
2+
 has probably no effect on the reaction with long alkyl chains.  
 
Figure 2.10: Chemical structures of various compounds involved in the synthesis. N-(3-Dimethylaminopropyl)-N′-
ethylcarbodiimidehydrochloride (EDC) (a), dicyclohexylcarbodiimide (DCC) (b), oxalyl chloride (c), and protoporphyrin 
IX(d). 
2.3.2. Purification of heme-DA analogues 
A Biotage
®
 KP-SIL SNAP column was used to purify heme-DA adducts. Samples were 
dissolved in a small volume of methylene chloride and introduced to the column on a Biotage
®
 
KP-SIL samplet. The conditions used were based on TLC experimentation performed in a 9:1 
chloroform:methanol mixture. Fractions that showed high absorbance at 280 nm were collected 
and analyzed by MS and the previous conditions were found to allow the efficient separation of 




DA from the mono-heme adduct several conditions were investigated; such as, 9:1 methylene 
chloride: methanol and 100% ethyl acetate. In addition reversed phase chromatography using a 
Biotage® KP-C18 SNAP column using 100% methanol and a 1:1 methanol:ethyl acetate mixture 
in two different experiments. Both bis- and mono-heme-DA were observed to elute at the same 
time due to the high similarity in structure and low polarity of both compounds, which have 
made the separation quite challenging (Figure 2.11). 
 
Figure 2.11: Fraction reports obtained from Biotage® Isolera chromatography system for purification of DA reaction 
mixtures with heme-NHS (A) and with hemin chloride in the presence of EDC (B) based on TLC conditions 9:1 methylene 
chloride: methanol. MS results of first peak fractions detected a mixture of mono and bis-heme DA adduct, whereas the 
second peak contained a mixture of free hemin, heme-mono-NHS and heme-bis-NHS along with some heme-DA 
analogues in A, and heme mono and bis EDC activated compounds in B.   
2.3.3. Attempts for incorporating heme-DA analogues into the His6-Bfr cage 
 Attempts for incorporating the modified heme involved incubating the apo-His6-Bfr Bfr 
with heme-DA analogues at 80 °C for 10 minutes, after which the mixture was then allowed to 
cool to room temperature. This methodology has been previously used by Anton van der Ven to 
incorporate different heme analogues into the Bfr structure.
80
 The added heme analogues were 
dissolved in either DMF or DMSO and then added to the buffered His6-Bfr solution. 





sulfoxide (DMSO) to the protein sample, which made the incorporation of these hydrophobic 
analogues a challenging task.  The success of incorporation was investigated by monitoring the 
change in the UV-Vis absorbance profile of the Bfr protein. The successful incorporation of the 
heme to the Bfr cage protein could be detected through the detection of the heme Soret band at 
around 420 nm in addition to the protein absorption signals at around 280 nm. However, in both 
trials no changes in the Bfr UV-Vis absorption profile were detected (Figure 2.12). Although 
DMF and DMSO are very compatible with the buffered protein samples, the precipitation of the 
heme-analogues out of solution upon their addition to the aqueous protein environment could 
prevent their introduction to the Bfr cage. 
 
Figure 2.12: UV absorption spectra obtained for hemin (orange) and heme-DA (green) His6-Bfr incorporation 
experiments. A control experiment of incorporating hemin in 0.2 MES buffer and 5% DMSO was analyzed and the heme 
Soret band at 420 nm was observed, in contrast in the heme-DA analogue incorporation experiment, no heme signal was 
























The results presented in this chapter indicate that the modification of heme with long 
alkyl chain labels is possible. The activation strategy followed to activate the heme propionate 
groups and the length of the added alkyl chains were found to affect the success of such 
reactions. In regard to the Bfr hydrophobic engineering approach that we are investigating, 
although we were able to synthesize and purify heme-DA analogues, the poor aqueous solubility 
















3. Chapter 3: Encapsulation of Hydrophobic Guest Molecules within the His6-Bfr Cavity. 
3.1. Introduction 
  Many chemotherapeutics are small molecular weight compounds which frequently have 
poor solubility in water. Poor water solubility can limit their therapeutic effects. During the past 
century, numerous studies aimed to optimize the therapeutic benefits of drugs while 
circumventing their systemic toxicity have been developed through the use of micellar drug 
systems (MDS) (Figure 3.1). The functional unit of a micellar drug carrier is the amphiphilic 
molecule; a molecule that has polar groups as well as nonpolar portions. These amphiphilic 
molecules are known to self-assemble into defined structures when exposed to solvents. In 
aqueus solutions, amphiphilic molecules pack in a way that expose their polar groups to the 
hydrophilic environment, while their hydrophobic portions are oriented away from the solvent, 
forming what is known as a regular micelle. Different types of amphiphilic molecules have been 
investigated as drug carriers and range from conventional surfactants to amphiphilic polymers.
94 
For example, a particular class of surfactant known as gemini surfactants, a surfactant containing 
two head groups that are connected by a linker, have attracted rigorous biological as well as 
biomedical interest as gene delivery platforms.
95,96
 Micellar drug delivery systems have several 
advantages; such as, simple preparation, increased drug solubility, increased circulation time 
coupled with reduced toxicity, enhanced tissue penetration and tissue targeting. However, they 
still have some limitations such as the systemic instability over long time periods, and the need 
for individualized system optimization for each drug.
97 
These limitations have resulted in an 
inadequate sustained drug release provided by such nanocarriers. Several approaches were 
investigated in order to address the issue of poor sustained drug release from micellar 





Figure 3.1: Structural illustration of some types of drug nanocarriers. This figure was modified from reference 97. 
3.1.1. Strategies for improved sustained drug release from micellar structures 
There have been several approaches toward optimizing drug release from micellar 
delivery systems; one of which has involved the encapsulation of prodrugs within the micelle 
core instead of using the drug in its free active form. In this case the conversion of the prodrug to 
an active drug in addition to the time required for micellar dissolution will increase drug 
retention levels. An example of this approach is the use of paclitaxel palmitate, a prodrug for 
paclitaxel, which was encapsulated in polyethylene glycol-b-polycaprolactone (PEG-b-PCL) 
micelles and exhibited an approximate 4-fold improvement in drug retention time in serum 
relative to paclitaxel itself, and also exhibited a better antiproliferative effect against cancer 
cells.
98
  The formation of drug-polymer conjugates is another effective strategy used to improve 
MDSs, which usually involves the conjugation of a drug to the hydrophobic portion of the 
amphiphilic polymer.
97




(DOX) to PLGA-PEG micelles and form an effective MDS.
99 
Moreover, amphiphilic block 
copolymers have shown promising potential for hydrophobic drug delivery; for instance, Pathak 
and coworkers have recently reported a PEG-based polyaspartic acid peptide-poly(ethylene 
glycol)-poly(ε-caprolactone) NP which was an excellent carrier for curcumin, a hydrophobic 
compound with reportedly high activity against bone metastasis, and exhibited good retention 
time, lower blood coagulation risks and higher antitumor activity.
100
 Other researchers have 
combined amphiphilic polymers with different structures to design novel polymeric MDSs; 
examples are the conjugation of copolymers with lipids
101
 and  polyaminoacids.
102
 In addition, 
oligopeptides have been used to prepare MDS for doxorubicin delivery, and their efficacy and 
toxicity were examined and compared to DOX; these more complex systems were found to have 
better anticancer effects with lower cytotoxicities.
103 
Another interesting class of amphiphilic-
based nanoparticles are the liposomes which are usually formed via self-assembly of 
phospholipids after dispersion in aqueous solvents. Liposomes have been utilized as drug carriers 
for both hydrophilic and hydrophobic drugs. The unique self arrangement of liposomes allows 
for hydrophobic drugs to be combined to the hydrophobic membrane bilayers during the 
liposome formation, while the aqueous core can serve as a reservoir for hydrophilic 
therapeutics.
104
 Despite the promising development in the design of MDSs, further progress 
toward longer sustained release and higher safety and tolerability is needed. 
In this chapter, previously discussed nickel-mediated affinity interactions between His6-
Bfr and guests carrying NTA functionalities will be utilized for the encapsulation of micellar 
structures within the cage protein cavity.  Such encapsulation could increase the versatility of the 
Bfr cage protein for delivering hydrophobic theranostics to their targets, as well as provide a 




the encapsulated drugs. Attempts to engineer the hydrophobicity of the inner cavity of the Bfr 
cage protein are of fundamental as well as practical interest towards potential molecular delivery 
applications. The encapsulation of two different amphiphilic guest molecules, 1,2-dioleoyl-sn-
glycero-3-[(N-(5-amino-1 carboxypentyl) iminodiacetic acid)succinyl] (nickel salt) (DGS-
NTA(Ni) and nonadecanoyl-NTA (ND-NTA), within the His6-tag Bfr cage protein will be 
outlined and discussed; and the micellar structures formed by these amphiphilic molecules under 
different conditions will be investigated. Molecular modelling on the fully extended ND-NTA 
indicated a length of 45 Angstroms which is the approximate radius of the interior cavity of Bfr; 
therefore ND-NTA would be the best first choic of fatty acids. The synthesis of single chain fatty 
acid-NTA, nonadecanoic-NTA, and His6-tag Bfr preparation and purification will be discussed 
in this chapter as well. 
As described earlier in Chapter 1, the His6-tag Bfr capsule protein contains 24 
hexahistidine tags which have been engineered onto the internally exposed C-termini of Bfr. 
These tags have been utilized successfully as specific affinity labels for encapsulation of guest 
molecules decorated with NTA functionalities. ProQ
®
 sapphire 365 oligohistidine stain, 
Streptavidin labelled with fluorescein and 1.8 nm and 5 nm gold nanoparticles (AuNP)
80
 are 
examples of NTA-containing guest molecules that have been successfully introduced to the 
His6-tag Bfr cavity by Dr. Honek’s graduate students. As there are 24 subunits that compose the 
quaternary structure of His6-tag Bfr, we aimed to utilize all 24 His6-tags toward introducing 
different kinds of fatty acid-based guest molecules into the Bfr cavity. For example, 
encapsulation studies of a micellar structure consisting of saturated single chain NTA-fatty acids 
(Figure 3.2), and different concentrations of non-saturated NTA lipid were performed in order to 






Figure 3.2: Structures of fatty acids involved in the His6-Bfr encapsulation studies. (A) Nonadecanoyl-NTA (C19-NTA). 
(B) A commercially available 18:1 DGS-NTA(Ni), 1,2-dioleoyl-sn-glycero-3-[(N-(5-amino-1 carboxypentyl) iminodiacetic 
acid)succinyl] (nickel salt) from Avanti Lipids, Incorporated. 
 
Four methods would be utilized to confirm the encapsulation of the micellar guests 
within the His6-Bfr: size exclusion chromatography (SEC), mass spectrometry, pyrene 
fluorescence, and transmission electron microscopy (TEM). Pyrene is a unique hydrophobic 
probe whose fluorescence spectrum has been previously used to characterize ND-NTA 
micelles,
105 
thus the encapsulation of pyrene-preloaded micelles can be detected through 
monitoring pyrene emission spectra. In addition to fluorescence analysis, TEM was pursued to 
characterize encapsulated micelles within the His6-Bfr cavity. Negative staining was performed 
using two types of stains; in this technique, the negative stain will create a layer in which protein 
structures will be embedded. According to the size of the stain molecules, some stains, atomic 
stains in particular, will penetrate through the pores of the protein shell and accumulate within its 
cavity. This methodology was previously utilized to confirm the encapsulation of guest 






cargos in the protein interior would exclude stain from the centre of the protein cage, and the 
absence of stain could be visualized and compared to the images of an empty protein cage.  
In addition to the previously listed analysis techniques, dynamic light scattering (DLS) 
would be employed to estimate the size of the engineered micelles under encapsulation 
conditions but in the absence of Bfr, and also utilized to investigate changes in the size of the 

















3.2.1. Materials  
All materials used in this section of the thesis are listed below otherwise they have been listed in 
Chapter 2. 
Nonadecanoic acid (NA) was purchased from Sigma Aldrich (Milwaukee, WI, USA), 
Nα,Nα-bis(carboxymethyl)-L-lysine hydrate (lysine NTA) (Sigma-Aldrich, Buchs, Switzerland, 
1,2-dioleoyl-sn-glycero-3-[(N-(5-amino-1 carboxypentyl) iminodiacetic acid)succinyl] (nickel 
salt) (DGS-NTA(Ni|) (Avanti Polar Lipids, AL, Alabama), Carbon 400 mesh, Cu Grids 
(Canemco-Marivac, Gore, QC, Canada), Molybdic acid ((NH4)6Mo7O24) (Sigma-Aldrich, Saint 
Louis, MO, USA), Phosphotungstic 39 acid (H3PW12O40) (Sigma-Aldrich, Saint Louis, MO, 
USA), All buffers were made with Milli-Q
TM
 water with 18 MΩ cm
-1
  resistivity and filtered 
through a  0.45 μm cut-off membrane. High purity pyrene was obtained from Dr. Duhamel’s 
laboratory.  
3.2.2. Safety statement 
Lab coat, gloves and protective glasses were used throughout all the experiments. 
Bacterial cultures were handled with extensive care and included working next to the flame and 
bleaching all the tools and glassware that came in contact with the bacteria. Experiments 
involving the use of organic chemicals like ethyl acetate or pyrene were performed in the fume 








3.2.3. Protein expression and purification 
Lysogeny broth (LB, 2 mL) containing ampicillin (30 μg/mL) was inoculated with a 
single colony of Escherichia coli BL21 culture with the E. coli Bfr gene engineered to have a C-
terminal His-tag contained on a plasmid.
80
 The mixture was shaken overnight (37 
o
C, 200 rpm), 
then added to 1.5 L of the liquid media containing ampicillin (30 μg/mL). After the culture 
reached its mid-log phase (optical density (OD) = 0.6-1.0), solid isopropyl-β-D-1-
thiogalactopyranoside (IPTG) was added to a final concentration of 1 mM to induce expression 
of the recombinant Bfr. Cells were shaken for four additional hours and then harvested by 
centrifugation at 17700g for 10 minutes. Cells were resuspended in Tris buffer (50 mM Tris, 100 
mM NaCl, pH 8.0) and then lysed utilizing a cell homogenizer (Avestin EmulsiFlex-C5). The 
resulting solution was spun down at 12000g for 20 minutes and the supernatant was collected.  
The supernatant was heat shocked at 70 
o
C and held at that temperature for 10 minutes, then left 
to cool to room temperature then centrifuged again at 12000g for 20 minutes. The supernatant 
was then collected for purification. The His6-tag containing Bfr was purified using a 1 mL GE 
His Trap
TM
 affinity column. The equilibration buffer was 50 mM Tris, 100 mM NaCl, and 20 
mM imidazole, at pH 8.0, while the elution buffer used was 50 mM Tris, 100 mM NaCl, and 300 
mM imidazole, at pH 8.0. The eluted proteins were analyzed using a 15% sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) gel and MS. Column fractions containing the 
desired protein were pooled and concentrated using an Amicon filtration apparatus with a 







3.2.4. Synthesis of nonadecanoyl-NTA (ND-NTA)  
The procedure for ND-NTA production was adapted from reference 105. Nonadecanoic 
acid (NA) (1 g, 3.3 mmol) and NHS (0.5 g, 4.9 mmol, 1.5 equiv.) were dissolved in 
dichloromethane (CH2Cl2, 50 mL) followed by the addition of 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC)-HCl (0.9 g ,4.9 mmol, 1.5 equiv.) The reaction was 
stirred for 24 h and then diluted with water (50 mL); the organic and aqueous phases were 
separated (Scheme 3.1). The aqueous phase was extracted 3 times using CH2Cl2 (20 mL). 
Organic phases were collected, washed with brine solution (50 mL), dried over anhydrous 
Na2SO4, filtered and concentrated under reduced pressure. The concentrated product was then 
recrystallized from hot ethyl acetate (EtOAc; 30 mL) to obtain a 0.8 g, 80 % yield, white powder 
of nonadecanoyl-NHS with a calculated molecular mass of 395.57 g/ mol (Scheme 3.1).   
 




 Nonadecanoyl-NHS (0.8 g, 2.02 mmol), Nα,Nα-bis(carboxymethyl)-L-lysine hydrate 
(lysine NTA) (0.5 g, 2.02 mmol, 1 equiv.) and triethylamine (NEt3) (1.9 ml, 14.14 mmol, 7 
equiv.) were dissolved in dry DMF (30 mL) and left to stir for 48 h at room temperature. The 
solvent was then evaporated and the residue was taken up in water (70 mL), acidified with 1 N 
HCl until precipitation started. Then the solution was stirred for one hour. The resulting 
suspension was then filtered and the white powder (0.7 g, 1.2 mmol, 70%) was dried under 
vacuum. The product, ND-NTA was analyzed with mass spectrometry and proton nuclear 
magnetic resonance (
1
H NMR) for chemical structure verification and purity. Micellar aqueous 
solutions of ND-NTA with different concentrations were prepared through raising the pH to 12 
through dropwise addition of 1 N solution of NaOH. pH was then lowered to 8 by addition of 1 
N HCl. An aliquot (60 µL) of each solution was analyzed with DLS to explore the size and 
behavior of the ND-NTA micelles in different solvent conditions. 
3.2.5. Encapsulation studies 
3.2.5.1. Encapsulation of ND-NTA micelle into His-6 Bfr 
ND-NTA (2 mg, 3.6 x 10
-6
 mol, 200 equiv.) was added to His6-Bfr (1.89 x 10
-9
 mol, 1.0 
equiv.) in 1 mL of 8 M guanidine hydrochloride (GdnHCl) buffered with 50 mM Tris, 100 mM 
NaCl at pH 8.0 along with nickel sulfate (4.5 x 10
-6
 g, 2.93 x 10
-8
 mol, 8.0 equiv.) and hemin 
chloride (1.9 x 10
-5
 g,  2.93 x 10
-8
 mol, 8 equiv.). This solution was kept for 90 minutes at 5 °C 
and was then dialyzed against 2 L of 50 mM Tris 100 mM NaCl buffer at pH 8.0 at 5 °C for 24 
h. The sample was concentrated with a Pall Nanosep
®
 spin column with a 10 kDa cut off to a 
volume of 0.250 mL. Encapsulated ND-NTA micelles were purified using a GE Sephacryl
TM
 S-
300HR resin, with a void volume of 99.05 mL, and running flow rate of 0.5 mL/min, collecting 




(24-mer Bfr) was collected, concentrated to 0.5 mL and analyzed using SDS page gel and MS, 
and viewed under TEM. 
3.2.5.2. Encapsulation of DGS-NTA(Ni) within His6-Bfr 
DGS-NTA(Ni) (0.95 mg, 9.07 x 10
-8
 mol, 48 equiv.) was added to His6-Bfr (1.89 x 10
-9
 
mol, 1.0 equiv.) in 1 mL of 8 M GdnHCl buffered with 50 mM Tris, 100 mM NaCl at pH 8.0 
along with hemin chloride (1.9 x 10
-5
 g,  2.93 x 10
-8
 mol, 8 equiv.). The mixture was kept for 90 
minutes at 5 °C before being dialyzed against 2 L of 50 mM Tris 100 mM NaCl buffer at pH 8.0 
at 5 °C for 24 hours. The sample was concentrated with a Pall Nanosep
®
 spin column with a 10 
kDa cut off to a volume of 0.5 mL. Similarly, encapsulated DGS-NTA(Ni) was purified using a 
GE SephacrylTM S-300HR resin, void volume of 99.05 mL, running flow rate was 0.5 mL/min, 
collecting fraction volumes of 1 mL. The running buffer was the same as the dialysis buffer. The 
second peak was collected, concentrated to 0.5 mL and analyzed with SDS page gel and MS, and 
viewed under TEM. 
3.2.6. TEM preparation and imaging 
  
Transmission electron microscopy experiments were performed on a CM10 Philips 
microscope modified with an Advanced Microscopy Techniques image capturing CCD camera.  
A 100 keV acceleration potential was used for imaging in bright field mode. A 400 mesh copper 
grid with a carbon-formvar coating was used to perform TEM imaging on the encapsulated ND-
NTA micelles. The optimum Bfr staining technique was previously established by Anton van der 
Ven
80
; two negative staining solutions were used to generate the contrast needed to visualize the 
protein:  0.5 % molybdic acid ((NH4)6Mo7O24), and 0.5% phosphotungstic acid (H3PW12O40). 
Encapsulated Bfr samples were prepared to a concentration of approximately 0.5 mg/mL. Grid 




one 20 µL droplet of stain on Parafilm
®
. The grid was placed on top of the sample droplet for 
one minute, then it was removed, dabbed with a piece of Whatmann No 1 paper to remove most 
of the liquid from the grid except for a thin glassy layer of solution. This was then washed by 
dipping the grid into the two water droplets as in the previous step without the minute wait time. 
Finally, grids were dipped onto the staining solution; excess stain was dabbed away until a thin 
glassy layer of solution coating the grid was left. Grids were covered and left at room 
temperature to dry for 24 h. 
3.2.7. MS experimentation  
 
All protein samples were buffer exchanged for water using Pall Nanosep® 10 kDa cut-off 
spin columns and then diluted to a final concentration of 1-5 μM in a 50 μL solution of a 1:1 
water: MeCN mixture with 0.2% formic acid or a 1:1 water:MeOH mixture with 0.1% formic 
acid and a 1:1 water:MeCN mixture with 0.5% NH4OH for samples containing DGS-NTA(Ni). 
Protein samples were run on a Thermo Scientific Q-Exactive
TM
 mass spectrometer. Spectra were 
collected between 100-2500 m/z and the supplied MaxEnt-1 MassLynx softwareA was used to 
deconvolute the protein mass. 
3.2.8. DLS sample preparation 
Samples for DLS analysis were first centrifuged at 7650g for 10 minutes and then filtered 
through Acrodisc syringe filters with a 0.2 µm membrane cut off. A volume of 60 µL of each 
sample was transferred to a Hellma Precision Quartz cell and finally submitted to Malvern 






3.2.9. Fluorescence spectroscopy studies using pyrene 
A stock solution of pyrene (2 × 10
−4
 M) was prepared in acetone. Two 10 µL aliquots of 
pyrene solution were transferred into two empty vials and the solvents were evaporated at 37 ◦C 
for 1 h. After evaporation, one vial was filled with 1 mL of ND-NTA (2 mg/mL) in Tris buffer 
(50 mM Tris, 100 mM NaCl) at pH 8.0 and gently stirred overnight at room temperature to 
ensure pyrene incorporation into the micelles. The other vial was used to perform the control 
experiment, where it was filled with 1 mL of 50 mM Tris and 100 mM NaCl buffer at pH 8 and 
allowed to stir overnight. These two solutions were then mixed with His6-Bfr, hemin chloride 
and NiSO4 and two separate encapsulation experiments were undertaken as described earlier in 
this chapter. Samples were purified as before employing a GE SephacrylTM S-300HR resin, a 
void volume of 99.05 mL, a running flow rate of 0.5 mL/min, and collecting fraction volumes of 
1 mL. Samples were concentrated to 1 mL for fluorescence spectroscopy analysis using a 
QuantaMaster instrument from Photon International Technology; a volume of 0.5 mL from each 
sample was transferred to Hellma Precision Quartz cell. Samples were excited at λ= 335 nm and 
pyrene emission spectra were recorded from 350 nm to 600 nm. Slit widths for the incoming and 
the emission light were set to 1 mm. Results were exported with PTI FeliX32 software and 










3.3. Results and Discussion 
3.3.1. His6-Bfr purification 
A 1 mL GE His Trap
TM
 affinity column was used to purify the His6-Bfr protein, and the 
supernatant from the homogenized cells was injected into the above the column. To determine 
the purity of the protein, fractions were examined using SDS-PAGE gel electrophoresis (Figure 
3.3 A) and fractions with higher purity were collected, pooled and concentrated using an Amicon 
stirred cell pressure concentrator with a Millipore Ultrafiltration membrane with a molecular 
weight cut off of 10 kDa. Protein samples were analyzed using a Thermo Scientific Q-
Exactive
TM
 mass spectrometer to confirm the molecular mass of the protein (19559 Da), whereas 
















Figure 3.3: Results of SDS-PAGE gel and MS analysis purified of His6-Bfr. (A) SDS-PAGE of the His6-tag Bfr fractions 
from chromatography. The lanes listed from right to left were fractions 8 and 5, and the PageRuler Unstained Protein 
ladder from Bio-Rad. The largest bands above the 15 kDa marker (~ 18.7 kDa) were His6-tag Bfr. (B) Mass spectrum of 
His6-tag Bfr obtained from using a Thermo Scientific Q-ExactiveTM mass spectrometer, raw spectrum (B) showed a 
Gaussian distribution of multiply charged His6-tag Bfr. (C) The processed spectrum was deconvoluted using the MaxEnt 
1 tool supplied with the MassLynx software, The deconvoluted mass was measured as 19559.22 Da, one mass unit 
different from the correct mass of 19560 Da. 
his bfr 2nd acqu #150-1003 RT: 0.19-1.26 AV: 854 NL: 2.18E6
T: FTMS + p ESI Full ms [500.00-2000.00]



































































3.3.2. Synthesis of ND-NTA  
ND-NTA was successfully synthesized from NHS activated NA as reported in reference 
103. Reaction yield was fairly good, 70%. Product was analyzed using 
1
H NMR 500 MHz to 
verify chemical structure and purity; samples were prepared in DMSO-d6 and our findings 
presented good agreement with what was reported in the literature (Figure 3.4 A).  Mass 
spectrometry analysis was performed using a Thermo Scientific LTQ Linear Ion Trap. The 
prominent peaks corresponded to ND-NTA of 543.42 which had a calculated molecular weight 
of 542.74 Da (Figure 3.4B). 
Solutions of ND-NTA with different concentrations were used to perform dynamic light 
scattering (DLS) experiments. The critical micellar concentration (cmc), the concentration at 
which amphiphilic molecules begin to form micelles, of ND-NTA was reported in reference 105 
to be 0.012 mg/mL or 0.02 mM. Concentrations used for DLS analysis were cmc/2, cmc, 2x cmc, 
4x cmc, 1 mM, and 2 mM. Although DLS is not a standard tool for measuring micelle size in 
absolute terms, it was very useful to obtain a rough estimation of the size of the ND-NTA 
micelles. Number- and volume-based distributions were used to obtain mode peak values of 
aggregation size for each concentration (Figure 3.5). Analysis of the results showed that ND-
NTA exhibits sharp transitions into micellization at concentrations of 1 mM and 2 mM with 
aggregate sizes of 7-10 nm. Thus a 2 mM concentration was used to perform the micelle 
encapsulation studies. Moreover, number and volume distribution results of 2 mM ND-NTA 
aqueous solution were compared to those of a 2 mM ND-NTA solution in the denaturing buffer 
system, consisting of 8 M GdnHCl with 50 mM Tris and 100 mM NaCl at pH 8, at which the 




found to be higher in the solvent with high solute concentration due to the effect of salts on the 
surface charges of surfactant head groups allowing the micelles to grow (Figure 3.6). 
 
Figure 3.4: Results of 1H NMR and MS analysis of synthesized ND-NTA. (A) 1H NMR (500 MHz) results were as 
following: 0.81-0.84 (3H, t), 1.21–1.44 (40H, m), 1.9-2.01 (2H, t), 2.9 (2H, d), 3.20–3.42 (12H, m), 7.6 (1H, t), nonintegrated 







        
 
Figure 3.5: Overlay of volume (A) and number (B) distribution analysis of DLS results of different concentrations of ND-


























    
       
 
Figure 3.6: DLS results of a number- (A&B) and volume- (C) based distributions of ND-NTA micelles in water and in 
denaturing buffer solution. ND-NTA micelles in water (A, green in C) exhibits an aggregation size of 7-10 nm while in the 
case of the denaturing buffer solutions (B, red in C) its aggregation size increased to 9-12 nm. Concentration of ND-NTA 
in these experiments was 2mM. 
 
3.3.3. ND-NTA micelle encapsulation 
Introduction of a ND-NTA micelle into the His6-Bfr cavity was achieved through mixing 
the His6-Bfr with ND-NTA, hemin chloride and NiSO4 in 8 M GdnHCl buffered with 50 mM 









NiSO4 was added to complete the metal mediated affinity interaction between the Bfr Histags 
and the NTA moieties, while hemin chloride was known to facilitate Bfr cage, 24-mer structures, 
formation. Dialyzed samples were concentrated and purified using SEC. Protein fractions were 
concentrated and analyzed on SDS-page gel electrophoresis, MS, and TEM. MS analysis 
indicated the presence of free ND-NTA monomers which have an expected mass of 542.5 g/mol, 
while deconvoluting the protein spectrum revealed the interaction between His6-Bfr monomer 
and ND-NTA(Ni) which was expected to have molecular mass of 20157 Da (Figure 3.7). 
 
 
Figure 3.7: MS results of ND-NTA micelle encapsulation experimentations. (A) Raw spectrum revealed a m/z of 540 
which corresponds to deprotonated ND-NTA which is expected to have a molecular mass of 542.5 g/mol. (B) The 
processed spectrum was deconvoluted using the MaxEnt 1 tool supplied with the MassLynx software, The deconvoluted 
mass of His-Bfr subunit was measured as 19559.22 Da, one mass unit off of the correct mass of 19560 Da, and the mass of 
His-Bfr subunit complexing with ND-NTA through one Ni atom was calculated as 20157.5 Da.  
 
 
mar13conc c19 nta his bfr #16-555 RT: 0.02-0.70 AV: 540 NL: 1.29E7
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3.3.4. TEM conditions and results 
The encapsulation of the ND-NTA micelle was confirmed by employing transmission 
electron microscopy (TEM). This technique had been utilized successfully to visualize 
encapsulated guest molecules such as AuNP and streptavidin within the His6-Bfr.
80
 Two TEM 
stains were used: Phosphotungstic acid and molybdic acid to visualize Bfr capsules and 
determine the presence of the encapsulated hydrophobic structures. Such atom sized stains were 
known to penetrate through the intrinsic pores found in the Bfr shell into the cavity. Based on the 
analysis of the TEM images, the ND-NTA micelles were large enough to fill most of the His6-
Bfr interior and thus exclude the stain away from the cavity. A lack of stain penetration would 
confirm the encapsulation of large micellar structures within the His6-Bfr lumen.    
Trials using phosphotugstic acid and molybdic acid stains were used at first to optimize 
the visualization of Apo-His6-Bfr, and the same stains were utilized to probe the presence of the 
ND-NTA micelle within the Bfr complex. Apo-Bfr images revealed the penetration of stains in 
to the Bfr core; however, some of the protein molecules lacked stain penetration, which could be 
due to the uneven distribution of the stain on the TEM grid or could be due to the low clarity of 
the images (Figure 3.8). Molybdic acid was chosen as the stain for subsequent studies. 
 
 Figure 3.8: Negatively stained TEM images of apo-His6-Bfr using molybdic acid (left) and phosphotungstic acid (right). 






TEM imaging results of His6-Bfr with likely encapsulated micelles were comparable to 
those of the apo His6-Bfr in terms of both morphology and size. Lack of stain penetration was 
clear where all protein structures were dull in color in comparison to the donut-shaped protein 
structures observed in the apo His-Bfr images (Figure 3.9), which are entirely consistent with 
micelle encapsulation within the His6-Bfr. Furthermore, the His6-Bfr capsules with micelles 
encapsulated appeared to be larger than the apo-His6-Bfr; diameter changes were estimated to be 
about 1.8-fold larger in diameter for the loaded protein capsules This result could be due to the 
large size of ND-NTA micelles and their hydrodynamic nature, which cause the protein cages to 
appear as swollen capsules accommodating such large guest structure. However, Bfr cages 
appeared to be less uniform in shape and size, which could be due to particles overlapping or 





Figure 3.9: TEM imaging results of apo-His6-Bfr and His6-Bfr encapsulating ND-NTA micelle stained by 0.5 M solution 
of molybdic acid. Donut-shaped appearance of apo-Bfr (left) indicates the penetration of the stain into the cage cavity, 
while the absence of stain penetration resulted in the dull sphere appearance of Bfr cages encapsulating the micelles 
(right). Magnified images of single protein particle showed a dark shell area surrounding a brighter cavity. Diameter 
analysis using ImageJ software of different protein particles demonstrated that micelles containing Bfr molecules 





3.3.5. Fluorescence studies of pyrene 
Pyrene has been widely used as a fluorescent probe to characterize various micellar 
solutions; intensities of pyrene emissions have been used to determine the critical micelle 
concentration (cmc) of different surfactants. Of interest to the current work, the use of pyrene 
emission patterns to confirm the cmc of ND-NTA was reported in reference 105. In this project, 
pyrene was first loaded into ND-NTA micelles and then pyrene-loaded micelles were introduced 
into His6-Bfr cages. SEC-purified His6-Bfr samples were analyzed using fluorescence 
spectroscopy to probe the existence of pyrene within Bfr cages and results were compared to 
standard pyrene-loaded ND-NTA micellar solutions (Figure 3.10). Pyrene emission spectra 
excited at λ= 335 exhibited vibronic patterns for both samples with λ 1 = 372 and λ 2 = 392, which 
is consistent with results reported in literature;
105
 however, pyrene vibronic bands from Bfr 
samples exhibited lower intensities. This could be due to the presence of heme in this sample that 
could absorb some of the pyrene energy as reported in the literature,
106
 in addition to the effect of 
the pyrene being placed in a slightly different environment, that of the protein cavity. Also, 
pyrene emission exhibited an extra band, termed an excimer, around 470 nm. This additional 
band usually appears when two fluorophores are spatially adjacent,
107
 which suggests that there 
is more than one pyrene molecule within the single ND-NTA micelle in both solutions. Emission 
based standard curve calculations were used to estimate the number of pyrene molecules within a 
single Bfr cage, which was able to accommodate a minimum of 6 pyrene equivalents (Appendix 
1). To verify the effect on pyrene fluorescence provided by heme quenching and the internal 
protein environment itself, pyrene-loaded protein cages were declustered using a denaturing 
buffer solution of GdnHCl. Pyrene emission spectra were collected after different time intervals 




intensity was observed (Figure 3.11). These results suggest that pyrene molecule emission is 
reduced within the encapsulated micelle due to a combination of self quenching as well as 
quenching due to the presence of heme molecules present in the protein. In addition, the pyrene 
excimer band at around 470 nm was not observed after the protein denaturation, which suggests 
that fluorophores were pulled away from each other probably due to micelle breaking after 
dilution. Moreover, in order to confirm that pyrene probe was dissolved within the encapsulated 
micelle in the previous study, a standard trial experiment for introducing pyrene into His6-Bfr 
was performed. Although the concentration of pyrene was very low to be encapsulated through a 
concentration gradient encapsulation pathway any hydrophobic interaction between pyrene and 
Bfr surface could result in a detection of pyrene within the Bfr sample; therefore, a similar 
encapsulation procedure was followed without addition of the amphiphilic compound, ND-NTA.  
 
Figure 3.10: Comparison of pyrene emission spectra obtained from 2 mM ND-NTA micellar solution (red) and pyrene-
loaded ND-NTA micelle within the Bfr cages (blue). Detailed RFU values for the blue scan can be obtained from Figure 
3.11.   
 

























Figure 3.11: Fluorescence spectroscopy results of pyrene-loaded ND-NTA micelle encapsulation. The lowest intensity plot 
(red) correspond to intact His6-Bfr cages containing pyrene dissolved within the micellar structure; upon denaturing 
about 5-fold enhancement in pyrene emission intensity was noticed after 10 minutes (dark blue) which gradually 
increased (30 minute, cyan) until an 8-fold (orange) increase in intensity after one hour under protein declustering 
conditions was observed. Also the pyrene excimer band at around 470 nm disappeared after declustering the protein. 
  
In addition, fluorescence spectroscopy results of the control experiment indicated that 
pyrene can not be introduced into the Bfr cage without being dissolved first within a micellar 
structure since no evidence of pyrene emission was detected that was associated with the protein 
(Figure 3.12); however, low emission signals were detected between 350 nm and 400 nm which 
probably correspond to the amino acid tryptophan from the Bfr subunits. For further 
confirmation an apo-His6-Bfr, heme-free sample at the same concentration was analyzed under 
the same excitation conditions and an identical emission profile was obtained. However, 
relatively higher emission intensity was observed in the heme-free protein sample which could 







































Figure 3.12: Fluorescence spectroscopy results of the control pyrene encapsulation experiment (blue) and apo-His6-Bfr 
solution (red). Emission spectra between 350 nm and 400 nm from both samples probably correspond to tryptophan from 
the Bfr protein.  
 
3.3.6. Encapsulation of DGS-NTA(Ni) within His6-Bfr 
An attempt to introduce DGS-NTA(Ni) lipid molecules into the His6-Bfr cavity was 
performed through the addition of DGS-NTA(Ni) to a solution of His6-Bfr in the presence of 
hemin chloride in a denaturing buffer solution. Reclustered protein cages were purified using 
size-exclusion column chromatography. First fractions from the gel filtration chromatography 
step were suspected to contain nanoparticles that were larger than His6-Bfr cage molecules, 
which usually elutes after 40 minutes (Figure 3.13); therefore, samples from the first fractions 
were collected and separated from those that were expected to contain the His6-Bfr protein, and 
both samples were visualized by TEM. Analysis of the MS results of the second set of fractions 
confirmed the presence of His6-Bfr protein as expected. DGS-NTA(Ni) was analyzed by MS to 
optimize its ionization and thus detection conditions. unfortanately, we were unable to detect any 
of the lipid using MS run in the positive ion mode while the use of negative ion mode provided a 
good ionization and an interpretable spectrum showing what could be the Na
+
 adducts of the 

























lipid detected at m/z
-
 1264. Protein signals were detectable using both the positive and negative 
ion modes; however, lipid signals were not detectable in the presence of the protein in the 
ionization field and they were observed later after the sample was removed and the ionization 
solution was run through the system (Figure 3.14). The reason could be that the high degree of 
ionization of the protein would probably suppress the ionization of the lipid and once the protein 
sample was discarded, the ionization of lipid molecules, which were still in the system, could be 
optimized. Analysis of the MS results suggests that DGS-NTA(Ni) could be successfully loaded 
into the Bfr cavity. Also, the concentration of pure protein cages obtained from this experiment 
was found to be lower than that of the ND-NTA micelle encapsulation which could be due to the 
association of protein subunits with the formed lipid aggregates. Therefore, further analysis using 
TEM and DLS was necessary in order to verify the lipid encapsulation, and investigate the nature 
of lipid aggregates that were formed during the experiment.  
 
Figure 3.13: Size exclusion chromatography results obtained at 260 nm for Apo-His6-Bfr (red) and DGS-NTA(Ni)-loaded 
His6-Bfr (blue). Early fractions collected after 30 minutes were suspected to contain aggregate that are larger than the 
Bfr cage protein, therefore they were collected and visualized under TEM separately.  
 











       
 
Figure 3.14: Mass spectrometry results of His6-Bfr encapsulating DGS-NTA(Ni). (A) Deconvoluted spectrum of mass 
expected for a single His6-Bfr subunit is detected at m/z of 19559.5. (B) Raw spectrum showing expected multi-sodium 
DGS-NTA(Ni) at m/z of 1264 after protein sample was discarded; however, traces of the multicharged protein signals can 
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3.3.6.1. TEM conditions and results 
A staining solution of 0.5 % molybdic acid was used to visualize protein molecules as 
previously described. TEM images revealed a lack of stain penetration into the protein core from 
most of the protein molecules which indicates that DGS-NTA(Ni) lipid molecules have been 
indeed encapsulated within the His6-Bfr cavity (Figure 3.15). In addition, it was observed that 
most of the protein molecules were slightly larger than expected; around 2 nm increases in 
diameter were measured in ImageJ software for protein particles with suspected encapsulated 
guest lipid. In contrast, empty protein molecules from the same grid had a diameter of 12.3 nm 
which is consistent with that of the apo-Bfr cage protein. 
 
Figure 3.15: TEM imaging results of DGS-NTA(Ni) encapsulation experiment. Protein molecules on the left presented 
lack of stain penetration along with a slight enhancement in size. Images of other part of the grid revealed some empty 
protein cages appeared as donut-shaped structures due to the penetration of stain into the core of the protein along with 
other protein structures which possibly were occupied by guest molecules, thus their cores were not stained.  
 
In addition, the first fractions from gel filtration chromatography were visualized under 
TEM and compared to those obtained from a solution of 18:1 DGS-NTA(Ni) (0.95 mg/mL); 
images of both samples revealed the formation of aggregates of different sizes ranging from 40 
nm to 120 nm (Figure 3.16). The excess DGS-NTA(Ni) observed from the encapsulation 





Figure 3.16: TEM imaging results of first fractions obtained from size exclusion chromatography (Right) and a prepared 
solution of DGS-NTA(Ni) at concentration of 0.95 mg/ml (Left). Aggregations of different sizes (40-120 nm) were 
observed in both samples. The shell-like structure observed in samples from the SEC fractions could be due to the 
attachment of protein subunits to the surface of the aggregates since similar interactions have been reported in the 
literature where DGS-NTA(Ni) was used to design protein coated liposomes.109 
 
3.3.6.2. DLS results 
 Samples of DGS-NTA(Ni) at two different concentrations, 1 mg/mL and 2 mg/mL, were 
analyzed using DLS. Although different studies have utilized the same lipid structures toward 
synthesis of liposomes,
109
 the behavior of these kinds of lipids at lower concentrations have not 
been clearly elucidated. Therefore, we utilized DLS to characterize the behavior of the guest 
lipid under concentrations close to what were utilized during the encapsulation experiments. 
Analysis have shown that the size of aggregates formed by DGS-NTA(Ni) lipids decreases as the 
concentration increases (Figure 3.17). Similar phenomena were observed in two studies with 
different kinds of lipid molecules.
110,111
 The reason for this behavior could be due to the 
increased access of the mono DGS-NTA(Ni) to the surface of the aggregates as its concentration 
increases which could have resulted in an increase in the surface curvature.
110
 Moreover a 
solution of DGS-NTA(Ni) in the denaturing buffer solution, consisting of 8 M GdnHCl, 50 mM 




concentrations on the morphology of such structures, however high concentration of solutes did 
not have any effect on the size of the DGS-NTA(Ni) aggregates (Figure 3.17). 
 
 
Figure 3.17: DLS size analysis results of 1 mg/mL and 2 mg/mL solutions of 18:1 DGS-NTA(Ni). Solutions of 
1 mg/mL DGS-NTA(Ni) in water (red) and in denaturing buffer (blue) exhibited aggregations with diameter 
around 120 nm, while a higher concentration of about 2mg/mL exhibited smaller aggregation size of about 45 
nm (green).   
 
 Moreover, DLS was utilized to compare the size of ND-NTA micelles and DGS-
NTA(Ni) loaded His6-Bfr to that of the apo-His6-Bfr to verify the TEM results. Analysis of the 
results confirmed the size increase in the His6-Bfr host after introducing the hydrophobic guests 
to its core (Figure 3.18). Confirming the TEM results, the largest size reported corresponded to 
ND-NTA micelles containing Bfr, with a diameter of about 16 nm, whereas the DGS-NTA(Ni)-








Figure 3.18: Typical number-based size distribution results of apo-His6-Bfr (red), His6-Bfr encapsulating DGS-NTA(Ni) 
(blue), and His6-bfr encapsulating ND-NTA micelles (green). Although DLS is not a standard technique to determine the 
actual size of particles, however in this case, DLS results confirmed previous TEM results that indicated an increase of 
the size of protein particles after encapsulating hydrophobic molecules. 
 
3.4. Conclusions 
 The results presented in this chapter indicate that His6-Bfr is able to accommodate 
hydrophobic guest molecules with NTA functionalities such as the ND-NTA micelle (Figure 
3.19). As described earlier, the size of the encapsulated cargos were found to strongly affect the 
size of the Bfr cage protein which have shown surprising flexibility to accommodate such large 
guest molecules. These findings could be employed towards the engineering of protein-based 
hydrophobic molecular delivery platforms.  
 
Figure 3.19: Illustration of a His6-Bfr with C19LysineNTA-Histag with linker shown in space fill in the centre of the 




4. Chapter 4: Future Prospects 
4.1. Introduction 
 The research presented in this thesis has extended the versatility of Bfr as a 
nanobioplatform in terms of chemical modification and molecular loading; however, further 
investigations are required in order to obtain a better understanding of the host-guest interaction 
and to further expand the capabilities of this protein. The synthesis of more hydrophobic heme 
analogues can be achieved and optimized based on the findings presented in Chapter 2, and a 
further improvement of purification yields of the heme-bis-amine analogues could be 
accomplished. Also the introduction of hydrophobic heme analogues to His6-Bfr could be 
achieved through the encapsulation of previous hydrophobic guest molecules such as ND-NTA, 
since the formation of a micellar environment within the system could improve the solubility of 
the hydrophobic heme analogues and thus its incorporation into the Bfr cage (Figure 4.1). 
Moreover, different carboxylic acids, shorter than nonadecanoic acid, can be used to synthesize 
alkyl chains with NTA functionalities; then additional encapsulation studies on smaller micelles 
can be investigated. 
 
Figure 4.1: An illustration of a His6-Bfr with C18alkylamine groups on the hemes shown in space fill in the centre of the 
protein. Also in the centre is shown the C19LysineNTA-Histag with linker and this is shown in space fill as well. Image 




4.2. Loading different hydrophobic drugs into the engineered His6-Bfr 
 As described in Chapter 3, the hydrophobic probe pyrene was successfully loaded into 
the His6-Bfr and released upon protein denaturation. The same procedure can be used to load 
hydrophobic compounds such as curcumin and Carmustine, also known as bis-chloronitrosourea 
(BCNU), (Figure 4.2) into the Bfr cage and then undertaking their evaluation against mammalian 
cell lines as they were previously utilized to evaluate other hydrophobic delivery scaffolds.
100,112
 
The encapsulation efficiency of some drugs such as haloperidol can be estimated through 






Figure 4.2: Structures of some hydrophobic compounds that might be loaded into the Bfr core through micelle 
encapsulation. 
 
4.3. Combining the hydrophobic engineering with the surface modification of His6-Bfr cage 
protein 
 As a delivery platform, it is critical to engineer the outer surface of the Bfr in order to 
improve the targeting specificity of this nanocarrier. The previous work on ferritin, which was 
discussed earlier in Chapter 1, could be applied to the Bfr cage protein; for instance affinity tags 
could be added to the outer surface of His6-Bfr such as RGD peptides
60




hydrophobic therapeutics into a tumor cell line. Moreover, Hawa Gyamfi, a Ph.D. candidate in 
the Honek laboratory, has studied several N-terminal extensions of the Bfr subunits; several Qtag 
and Sort tag sequences have been added to the N-terminal methionine (Figure 4.3). The Qtags 
are glutamine-containing peptides that are substrates for the enzyme transglutaminase. They 
would be used to link on a new amine to the glutamine thus to the Bfr surface. For instance, Ms. 
Gyamfi has already shown that transglutaminase can replace the “NH2” of the glutamine in the 
tag with dansyl cadaverine, a fluorescent amine, which was successfully added to the Bfr 
subunits. The SortTag would be useful with an enzyme called sortase, whose reaction is shown 
in Figure 4.4. It is another way to attach proteins or peptides to the surface of Bfr using the 
enzyme sortase. This work could be used in future to direct our engineered His6-Bfr delivery 
system to material surfaces or cells. 
 
Figure 4.3: Constructs of some of the tags that were successfully added to the external N-termini of the Bfr subunits. The 
top sequence shown in black is for a His6-Bfr subunit. Different tags are displayed in the table where the linker region is 








Figure 4.4: Schematic illustration of the sortase mediated reaction to add proteins or peptides to the surface of Bfr. 
The SortTag1 sequence would be displayed on the surface of Bfr, a protease would be required to trim back this exposed 
sequence to produce “GGGGGMKGD…” which is necessary for the sortase reaction. This new Bfr would be the 
nucleophile that would be used by sortase to react with any peptide or protein that had a C-terminus sequence 
“….LPXTGXX” The sortase reacts with this protein/peptide. The sortase forms an activated thioester and the N-
terminus of the GGGGG-Bfr reacts and displaces the sortase enzyme, forming a new attachment to the surface of Bfr. 
 
 Moreover, enhancement of cell internalization of the engineered His-Bfr system 
through the attachment of types of cell permeable peptides (CPP) onto the surface of His6-Bfr, 
which could be attached through formation of disulfide linkage to engineered surface cysteines, 
could be investigated. The CPPs are short sequences of positively charged amino acids that are 
known for their ability to traverse the cell membrane.
114 
these peptides have been previously 
utilized to facilitate cell penetration and internalization of different protein-based therapeutic 
cargos.
115,116 
The success in delivering our engineered nanocarrier into cells would highlight 
novel drug delivery applications and could be employed toward the development of promising 
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Appendix 1: Standard curve calculations used to estimate the number of pyrene molecules 






X - 70381                              X is the concentration of pyrene in the His6-Bfr sample  
RFUpy-Bfr= 274556 
X= 158556 + 70381/ 3× 10
6
 
X= 0.076 mg/mL or 0.37 mM 
The concentration of the Bfr in the sample= 0.06 mM. 
The number of equivalents of pyrene per a protein cage= 6.17 
However, this result is only an estimate of the number of pyrene molecules within a single Bfr 
capsule since the emission intensity in the protein sample could be reduced by different factors 




y = 3E+06x - 70381 
R² = 0.9888 
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